# Novo Nordisk Reports New CagriSema Weight-Loss and Function Findings By John Kim Canonical URL: https://www.tokenpost.com/news/business/57902 Published: 2026-11-15T20:27:59.000Z Updated: 2026-11-15T20:27:59.000Z Section: Business > Two additional REDEFINE 1 analyses found differing weight-loss patterns and improved daily functioning among adults receiving the experimental treatment. Novo Nordisk announced two additional analyses of its late-stage REDEFINE 1 trial. The analyses found differing weight-loss patterns among adults receiving CagriSema, the company’s experimental obesity treatment. A separate analysis found improvements in daily functioning among adults receiving CagriSema. CagriSema combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, which acts on a pathway involved in hunger and fullness. The late-stage REDEFINE 1 trial included roughly 3,400 adults with obesity or overweight, and roughly two-thirds of participants were women. Earlier CagriSema findings from REDEFINE 1 focused on women and menopause classifications. That analysis estimated average weight loss of 25% among women over 68 weeks, assuming participants remained on treatment. A [previous analysis of women in REDEFINE 1]() covered those results. ## Links in this article - [previous analysis of women in REDEFINE 1](https://www.tokenpost.com/news/business/35960)